Company description

Cytokinetics, Inc. (ticker symbol CYTK) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel muscle activators and other small molecule therapies for the treatment of diseases involving muscle dysfunction and fatigue. The company uses its expertise in muscle biology to develop innovative therapies for conditions such as heart failure, neuromuscular disorders, and spinal muscular atrophy. Cytokinetics' lead product candidate, omecamtiv mecarbil, is being evaluated in clinical trials for the potential treatment of heart failure. The company also has a strong pipeline of other drug candidates in various stages of development. With a commitment to advancing science and improving patients' lives, Cytokinetics is dedicated to being a leader in the field of muscle biology and therapeutics.